The company listed on the ASX in the midst of the pandemic and has seen global demand for its COVID-19 tests. Mr Kelly said throughout the pandemic, government and media focus had remained on bigger players like CSL, but the country needed to also focus on how to help smaller players commercialise technologies they already had. “Australia spends an awful lot of money on research, but it’s a hard place to get research commercialised.”
He said any investment plans to empower Australian manufacturing and growth should be made as easy as possible for earlier stage companies to access, “rather than having closed channels and just people already in the club”.
Chief executive of ASX-listed prescription management business MedAdvisor, Robert Read, said the focus on leveraging medical technologies for an economic recovery was exciting, but not enough focus was being placed on the digital technologies behind the scenes.
MedAdvisor’s platform lets users track and store information about their prescriptions as well as ordering medications online for delivery. It recently made a $49 million acquisition of a US prescription management system Adheris with plans to make a big launch in America.
“It [digital health technology] is always a ‘by the way’ or ‘icing on the top of the cake’ type thing, yet it can be so impactful,” Mr Read said.
Chief executive of digital health business accelerator ANDHealth, Bronwyn Le Grice, says the state’s new $2 billion Breakthrough Victoria fund must consider investing in digital health and connected technologies amid the rise of telehealth and connected devices across the health system.
“Now is not the time to just do what we have done before. This [fund] could literally transform Victoria’s future. If it just reinvests back into traditional manufacturing, the sector will always be strong, but we’re missing out,” she said.
Chief executive of ASX-listed Telix Pharmaceuticals, Christian Behrenbruch, said Victoria and Australia could only reach its full potential as a medical technology powerhouse if policymakers committed to consistent approaches to less flashy policy measures, like talent recruitment and tax incentives.
“It’s not flashy, or splashy, but it’s things like our immigration policy [that are important]. With skilled visa programs for life sciences, it’s not consistent, very reactive and constantly a moving target.”
Mr Behrenbruch, whose company is working on new approaches for imaging and treating cancers including brain and prostate, said the recognition that Victoria and Australia could boost returns from research investment was a big win, but there was more work to do make it easier for local companies to recruit the best staff available.
“You can have an excellent building but if you can’t fill it with talent, you’re probably going to struggle.”
Emma reports on healthcare companies for The Age and Sydney Morning Herald. She is based in Melbourne.